Apogee Therapeutics, Inc.
No enriched coverage for $APGE in the last 7 days.
Apogee Therapeutics (NASDAQ:APGE) reported Q2 2026 results with $1.3B cash and an $85.9M net loss. The loss reflected $67.3M R&D and $24.3M G&A, as spending on its zumilokibart program increased. The company said its directors will resign at closing of an AbbVie deal, after which APGE becomes an indirect wholly owned AbbVie subsidiary.
Apogee Therapeutics, Inc. (APGE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”)
Apogee Therapeutics, Inc. (APGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worl
Recent APGE coverage spans mergers & acquisitions, insider activity and corporate actions.
In the last 30 days, APGE insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($738K). The most active reporter was Dambkowski Carl, Chief Medical Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The article frames a near-term governance change tied to the AbbVie deal, alongside ongoing cash burn and higher zumilokibart spending.
The 8-K confirms shareholder approval mechanics for the AbbVie merger, reducing one key closing uncertainty while leaving the non-binding compensation vote without effect.
The AbbVie cash buyout and new clinical readouts materially change APGE’s deal and development risk profile.
This is a routine 10b5-1 insider sale disclosure, not a fundamental company update, but it can still affect near-term sentiment.
The article reinforces that APGE is in an announced AbbVie acquisition, with a defined offer price and a premium that can anchor trading and spread behavior.
alphai scores every news story that mentions APGE with an AI model for sentiment and relevance, and aggregates insider trades from Apogee Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Apogee Therapeutics (NASDAQ:APGE) reported Q2 2026 results with $1.3B cash and an $85.9M net loss. The loss reflected $67.3M R&D and $24.3M G&A, as spending on its zumilokibart program increased. The company said its directors will resign at closing of an AbbVie deal, after which APGE becomes an indirect wholly owned AbbVie subsidiary.
1 min readApogee Therapeutics, Inc. (APGE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”)
2 min readApogee Therapeutics, Inc. (APGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worl
6 min readDambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $134.17 ($0.74M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readBaron Health Care Fund’s Q2 2026 investor letter reported the fund gained 11.99% in the quarter. It said it sold Apogee Therapeutics (NASDAQ:APGE) after Apogee agreed to be acquired by AbbVie (AbbVie Inc.) for $135.11 per share, a 49.5% premium. APGE closed at $134.19 on Aug. 4, 2026.
2 min readAbbVie (ABBV) said June 22 it will acquire Apogee Therapeutics (APGE) for $10.9 billion in cash. The deal would add zumilokibart for eczema to AbbVie’s immunology portfolio. The article discusses potential effects on AbbVie’s dividend, citing AbbVie’s 2025 free cash flow estimate of $17.8 billion and its dividend growth record.
7 min readPwC estimates over $300 billion in branded pharma revenue will lose patent exclusivity by decade end, driving large drugmakers to buy pipelines. ALPS Advisors says biopharma deal value could exceed $250B in 2026. The ALPS Medical Breakthroughs ETF (SBIO) added 37 names in June; it holds ABBV’s $10.9B Apogee deal target APGE and Definium (DFTX).
7 min readApogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson filed an SEC Form 4 showing he disposed of 95,046 shares on July 8 and July 10, 2026. Of this, 75,046 shares were gifted to a donor-advised fund and 20,000 were sold under a Rule 10b5-1 plan. Henderson retained about 920,941 shares. APGE reported a TTM net loss of $274.6 million and its stock rose about 247% over the prior year.
7 min readHENDERSON MICHAEL THOMAS (Chief Executive Officer) sold 20,000 shares of Apogee Therapeutics, Inc. (APGE) at $133.63 ($2.67M total) on 2026-07-08 under a Rule 10b5-1 trading plan.
2 min readDambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $132.74 ($0.73M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min read
